Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22271443 | 0.82 | PRKCG (0.35) | PRKCGPRKCAPRKCDPTGS2 | |
| SCHEMBL22271596 | 0.82 | ALDH1A1 (0.36) | PRKCGPRKCAPRKCDPTGS2 | |
| SCHEMBL2761891 | 0.79 | PRKCG (0.43) | PRKCGPRKCAPRKCDPTGS2KDM4E | |
| SCHEMBL30453457 | 0.77 | PRKCG (0.32) | PRKCGPRKCAPRKCD | |
| SCHEMBL24570668 | 0.77 | PTGS2 (0.36) | PRKCGPRKCAPRKCDPTGS2 | |
| SCHEMBL25350958 | 0.77 | PRKCG (0.32) | PRKCGPRKCAPRKCD | |
| SCHEMBL25354231 | 0.77 | PTGS2 (0.33) | PRKCGPRKCAPRKCDPTGS2 | |
| SCHEMBL26606588 | 0.77 | PRKCG (0.36) | PRKCGPRKCAPRKCDPTGS2 | |
| SCHEMBL22271535 | 0.73 | ATM (0.46) | MAPT | |
| SCHEMBL12611103 | 0.73 | PRKCG (0.40) | PRKCGPRKCAPRKCDPTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | PRKCG 2163/4885PRKCA 2209/4885PRKCD 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.